NEWS
Paul Hastings Advises Lightspeed Venture Partners in Series F Financing for Orca Bio
January 12, 2026
Paul Hastings LLP advised Lightspeed Venture Partners as lead investor in a Series F financing round for Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy.
Proceeds from the financing round will be used to ensure commercial readiness as the company approaches the April 6, 2026, Prescription Drug User Fee Act target action date for Orca-T, Orca Bio’s lead investigational allogeneic T-cell immunotherapy.
Partner David Ambler led the Paul Hastings team, which included of counsel Mary Wilbourn and associate Laura Jetter.
More details can be found here.
About Paul Hastings
With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.